Loading...
Market
What will be Pfizer's top-selling product category in 2024?
2
Resolution / Starting Odds
Cancer drugs • 25%
COVID-19 treatment • 25%
Vaccines • 25%
Other pharmaceuticals • 25%
Pfizer's annual report for 2024
Story
Pfizer Raises Profit Forecast by $1.5B, Beats Earnings Amid Starboard Pressure
Oct 29, 2024, 11:02 AM
Pfizer Inc. reported better-than-expected third-quarter earnings on Tuesday, fueled by strong demand for its cancer drugs and COVID-19 treatment. The U.S. drugmaker raised its full-year profit forecast and increased its 2024 guidance by $1.5 billion, signaling confidence amid pressure from activist hedge fund Starboard Value to demonstrate a turnaround. Pfizer now expects core operating income growth in the high teens. Adjusted earnings per share were $1.06, surpassing analysts' estimates of $0.62. Revenue topped expectations at $17.7 billion versus the forecasted $14.92 billion. The positive results mark a significant moment for CEO Albert Bourla as the company faces scrutiny over its strategic direction.
View original story
Similar markets
Covid vaccine • 25%
Paxlovid • 25%
Other Pharmaceutical Product • 25%
Other Vaccine • 25%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
Migraine medication • 25%
COVID-19 medication • 25%
Flu medication • 25%
Respiratory illness medication • 25%
Pandemic-related products • 25%
Oncology • 25%
Vaccines • 25%
Other • 25%
Diagnosis • 25%
Prescribing • 25%
Vaccine scheduling • 25%
Prescription fulfillment • 25%
COVID-19 Vaccine • 25%
RSV Vaccine • 25%
Other Products • 25%
No clear top-seller • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Yes • 50%
No • 50%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Below Top 3 • 25%